(2S)-2-amino-3-methylbutanoic acid;4-butyl-1,2-diphenylpyrazolidine-3,5-dione

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-amino-3-methylbutanoic acid;4-butyl-1,2-diphenylpyrazolidine-3,5-dione
• 化学式: C24H31N3O4
• 分子量: 425.5
• InChiKey: MZIKMBKVTSASNE-VWMHFEHESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.84
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• IMMUNOGENIC COMPOSITIONS AND A PROCESS FOR PRODUCING SAME
  申请人：THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD

  公开号：EP2970919A1

  公开（公告）日：2016-01-20
• Immunogenic compositions and a process for producing same
  申请人：THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD

  公开号：US20160122395A1

  公开（公告）日：2016-05-05

  The present invention provides a modified HIV envelope glycoprotein (Env) antigen or a lipid containing vehicle comprising same. The Env antigen comprises one of a second site suppressor mutation in residue 674 of the membrane proximal ectodomain region (MPER) of HIV gp41; a second site suppressor mutation which ablates a glycosylation site in the variable region (V1) region of gp120; or a second site suppressor mutation ablating a glycosylation site in the V1 region of gp120 and a second site suppressor mutation in residue 674 of the MPER of HIV gp41. It is preferred that the lipid containing vehicle is a HIVLP.
• HIV VACCINATION COMPOSITIONS
  申请人：ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY

  公开号：US20190328864A1

  公开（公告）日：2019-10-31

  Disclosed are compositions for generating an immune response against human immunodeficiency virus (HIV) and their methods of uses.
• [EN] IMMUNOGENIC COMPOSITIONS AND A PROCESS FOR PRODUCING SAME<br/>[FR] COMPOSITIONS IMMUNOGÈNES ET LEUR PROCÉDÉ DE PRODUCTION
  申请人：MACFARLANE BURNET INST FOR MEDICAL RES & PUBLIC HEALTH LTD

  公开号：WO2014138825A1

  公开（公告）日：2014-09-18

  The present invention provides a modified HIV envelope glycoprotein (Env) antigen or a lipid containing vehicle comprising same. The Env antigen comprises one of a second site suppressor mutation in residue 674 of the membrane proximal ectodomain region (MPER) of HIV gp41; a second site suppressor mutation which ablates a glycosylation site in the variable region (VI) region of gpl20; or a second site suppressor mutation ablating a glycosylation site in the VI region of gpl20 and a second site suppressor mutation in residue 674 of the MPER of HIV gp41. It is preferred that the lipid containing vehicle is a HIVLP.